Regeneron Announces January 2013 Investor Conference Presentations
TARRYTOWN, N.Y., Dec. 20, 2012
TARRYTOWN, N.Y., Dec.20, 2012 /PRNewswire/ --Regeneron Pharmaceuticals, Inc.
(NASDAQ: REGN) will webcast management presentations at the following investor
oGoldman Sachs Healthcare CEOs Unscripted: A View from the Top on
Thursday, January 3, 2013. The session is scheduled for 3:15 p.m. Eastern
o31^st Annual J. P. Morgan Healthcare Conference on Tuesday, January 8,
2013. The presentation is scheduled for 7:30 a.m. Pacific Time (10:30
a.m. Eastern Time).
The sessions may be accessed through the Company's web site,
www.regeneron.com, on the 'Events and Presentations' page. An archived
version of the presentation will be available for 30 days.
Regeneron is a fully integrated biopharmaceutical company that discovers,
invents, develops, manufactures, and commercializes medicines for the
treatment of serious medical conditions. Regeneron markets three products in
the United States, EYLEA^® (aflibercept) Injection, ZALTRAP^®
(ziv-aflibercept) Injection for Intravenous Infusion, and ARCALYST^®
(rilonacept) Injection for Subcutaneous Use; ZALTRAP is co-commercialized with
Sanofi. Phase 3 studies are in progress with EYLEA in two additional
indications and with product candidates sarilumab and REGN727. Regeneron has
active research and development programs in many disease areas, including
ophthalmology, inflammation, cancer, and hypercholesterolemia. Additional
information and recent news releases are available on the Regeneron web site
Michael Aberman, M.D. Peter Dworkin
Investor Relations Corporate
SOURCE Regeneron Pharmaceuticals, Inc.
Press spacebar to pause and continue. Press esc to stop.